SDOX

SDOX is the Doxorubicin (DOX) proagent. The loaded DOX proagents (SDOX) which can release the parent agents DOX triggered by excessive GSH in tumor cells, minimize the unexpected side effects on normal tissues without compromising the potency[1].

Product Specifications

CAS Number

[2921601-78-5]

UNSPSC

12352005

Target

Topoisomerase

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/sdox.html

Solubility

10 mM in DMSO

Smiles

C[C@@]12[C@]3([H])[C@](CC=C1C[C@H](CC2)OCCOCCOCCOC(CCC(OCCSSCCOC(N[C@H]4C[C@@H](O[C@H]([C@H]4O)C)O[C@@H]5C6=C(C[C@](O)(C5)C(CO)=O)C(O)=C7C(C(C8=C(OC)C=CC=C8C7=O)=O)=C6O)=O)=O)=O)([H])[C@@]9([H])[C@](CC3)([C@@](CC9)([H])[C@H](C)CCCC(C)C)C

Molecular Formula

C69H97NO20S2

Molecular Weight

1324.63

References & Citations

[1]Yi Zhao, et a l. pH-redox responsive cascade-targeted liposomes to intelligently deliver doxorubicin prodrugs and lonidamine for glioma. Eur J Med Chem. 2022 May 5;235:114281.